Tech Company Financing Transactions
Spore.Bio Funding Round
Singular, Famille C and private investors participated in a $23 million Series A funding round for Spore.Bio. The round was announced on 2/20/2025.
Transaction Overview
Company Name
Announced On
2/20/2025
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series A
Investors
Singular (Lead Investor)
private investors (David Prior)
Proceeds Purpose
The company intends to use the funds to double its workforce from 25 to 50 scientists and engineers, scale up the industrialization process, continue to iterate with existing customers and prepare for commercialization before the end of the year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
96, Boulevard Raspail
Paris, Île-de-France, 75006
FR
Paris, Île-de-France, 75006
FR
Phone
Undisclosed
Website
Email Address
Overview
Building a new generation of microbiological technologies. Developer of a bacterial detection technology designed to develop innovative technological tools to help the food and beverage industry. The company is directly useable on the shop floor, thereby, combining cutting-edge optical technology with advanced machine-learning models, enabling cosmetics and pharmaceutics factories to help factories manufacture safe products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amine Raji
Chief Operating Officer
Mohamed Tazi
Chief Technical Officer
Maxime Mistretta
Browse more venture capital transactions:
Prev: 2/20/2025: RepScan venture capital transaction
Next: 2/20/2025: Valar Atomics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs